SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 9/22/20 Obalon Therapeutics Inc. 8-K:5 9/16/20 1:37K |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 23K
Document |
26-1828101 | ||
(Commission File Number) | (IRS Employer Identification
No.) |
5421 Avenida Encinas, Suite F | ||
(Address
of principal executive offices) | (Zip Code) |
¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common stock, par value $0.001 per share | OBLN | The
NASDAQ Stock Market LLC (NASDAQ Global Market) |
Item 5.07 | Submission
of Matters to a Vote of Security Holders. |
Name | Votes For | Votes Withheld | Broker
Non-Votes |
Douglas Fisher, M.D. | 2,012,617 | 91,194 | 3,168,032 |
Sharon Stevenson, DVM Ph.D. | 2,012,248 | 91,563 | 3,168,032 |
William Plovanic | 2,004,282 | 99,529 | 3,168,032 |
Votes For | Votes Against | Abstentions | Broker Non-Votes |
5,098,733 | 141,919 | 31,191 | 0 |
OBALON THERAPEUTICS, INC. | |||
Date:
September 22, 2020 | By: | /s/ Andrew Rasdal | |
President
and Chief Executive Officer |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
12/31/20 | 10-K | |||
Filed on: | 9/22/20 | |||
For Period end: | 9/16/20 | 4, DEF 14A | ||
8/7/20 | 8-K, DEF 14A | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/03/21 ReShape Lifesciences Inc. S-8 2/03/21 3:211K Toppan Merrill Bridge/FA |